Emergent BioSolutions (NYSE:EBS) Shares Down 11%

Emergent BioSolutions Inc. (NYSE:EBS) was down 11% during trading on Thursday . The company traded as low as $11.14 and last traded at $11.31. Approximately 1,027,926 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 3,796,579 shares. The stock had previously closed at $12.71.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, July 2nd.

Emergent BioSolutions Trading Down 4.4 %

The firm has a market capitalization of $529.76 million, a PE ratio of -0.92 and a beta of 1.62. The company has a quick ratio of 0.55, a current ratio of 1.08 and a debt-to-equity ratio of 0.67. The business’s fifty day moving average price is $8.40 and its 200 day moving average price is $4.66.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. The business had revenue of $300.40 million for the quarter. During the same period in the prior year, the business posted ($3.17) earnings per share. As a group, analysts expect that Emergent BioSolutions Inc. will post -1.98 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Kathryn C. Zoon sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the sale, the director now directly owns 54,482 shares of the company’s stock, valued at $332,885.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 12,919 shares of company stock valued at $75,831. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Emergent BioSolutions by 14.7% during the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after buying an additional 436,911 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after purchasing an additional 1,312,934 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Emergent BioSolutions by 0.6% during the first quarter. Assenagon Asset Management S.A. now owns 839,414 shares of the biopharmaceutical company’s stock worth $2,124,000 after purchasing an additional 5,042 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Emergent BioSolutions by 1.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock worth $1,105,000 after purchasing an additional 6,724 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of Emergent BioSolutions by 20.1% during the first quarter. Los Angeles Capital Management LLC now owns 193,991 shares of the biopharmaceutical company’s stock worth $491,000 after purchasing an additional 32,460 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.